Immunotherapy of hepatoma with a monoclonal antibody against murine endoglin

World Journal of Gastroenterology

Volumn 13, Issue 17, 2007, Pages 2479-2483

  Tan, Guang Hong ^a   Huang, Feng Ying ^a   Wang, Hua ^a   Huang, Yong Hao ^a   Lin, Ying Ying ^a   Li, Yue Nan ^a  

^a HAINAN MEDICAL UNIVERSITY   (China)

Author keywords

Apoptosis; Endoglin; Monoclonal antibody; Passive immunotherapy; Tumor angiogenesis

Indexed keywords

ALGINIC ACID; CD31 ANTIGEN; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY ENDOGLIN; UNCLASSIFIED DRUG;

AFFINITY CHROMATOGRAPHY; ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CANCER SURVIVAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE MODEL; DRUG EFFICACY; IMMUNOASSAY; IMMUNOHISTOCHEMISTRY; IN VIVO STUDY; INHIBITION KINETICS; LIVER CELL CARCINOMA; MICROVASCULATURE; MOUSE; NICK END LABELING; NONHUMAN; PURIFICATION; SIGNAL TRANSDUCTION; SURVIVAL TIME; TUMOR CELL; TUMOR VASCULARIZATION; TUMOR VOLUME;

EID: 34250676898     PISSN: 10079327     EISSN: None     Source Type: Journal    
DOI: 10.3748/wjg.v13.i17.2479     Document Type: Article

References (34)

1. Pisani P, Parkin DM, Bray F, Ferlay J, Estimates of the worldwide mortality from 25 cancers in 1990. Int J Cancer 1999; 83: 18-29
2. Parkin DM. Global cancer statistics in the year 2000. Lancet Oncol 2001; 2: 533-543
3. Okuda K. Hepatocellular carcinoma. J Hepatol 2000; 32: 225-237
4. Gougos A, Letarte M. Identification of a human endothelial cell antigen with monoclonal antibody 44G4 produced against a pre-B leukemic cell line. J Immunol 1988; 141: 1925-1933
5. Fonsatti E, Sigalotti L, Arslan P, Altomonte M, Maio M. Emerging role of endoglin (CD105) as a marker of angiogenesis with clinical potential in human malignancies. Curr Cancer Drug Targets 2003; 3: 427-432
6. Duff SE, Li C, Garland JM, Kumar S. CD105 is important for angiogenesis: evidence and potential applications. FASEB J 2003; 17: 984-992
7. She X, Matsuno F, Harada N, Tsai H, Seon BK. Synergy between anti-endoglin (CD105) monoclonal antibodies and TGF-beta in suppression of growth of human endothelial cells. Int J Cancer 2004; 108: 251-257
8. Li YN, Tan GH, Jiao JG, Huang FY, Jiang J. Establishment of a monoclonal antibody against extracellular domain of murine endoglin. Zhongguo Xiandai Yixue 2007; 17: 1-4
9. Tan GH, Wei YQ, Tian L, Zhao X, Yang L, Li J, He QM, Wu Y, Wen YJ, Yi T, Ding ZY, Kan B, Mao YQ, Deng HX, Li HL, Zhou CH, Fu CH, Xiao F, Zhang XW. Active immunotherapy of tumors with a recombinant xenogeneic endoglin as a model antigen. Eur J Immunol 2004; 34: 2012-2021
10. Wei YQ, Huang MJ, Yang L, Zhao X, Tian L, Lu Y, Shu JM, Lu CJ, Niu T, Kang B, Mao YQ, Liu F, Wen YJ, Lei S, Luo F, Zhou LQ, Peng F, Jiang Y, Liu JY, Zhou H, Wang QR, He QM, Xiao F, Lou YY, Xie XJ, Li Q, Wu Y, Ding ZY, Hu B, Hu M, Zhang W. Immunogene therapy of tumors with vaccine based on Xenopus homologous vascular endothelial growth factor as a model antigen. Proc Natl Acad Sci USA 2001; 98: 11545-11550
11. He QM, Wei YQ, Tian L, Zhao X, Su JM, Yang L, Lu Y, Kan B, Lou YY, Huang MJ, Xiao F, Liu JY, Hu B, Luo F, Jiang Y, Wen YJ, Deng HX, Li J, Niu. T, Yang JL. Inhibition of tumor growth with a vaccine based on xenogeneic homologous fibroblast growth factor receptor-1 in mice. J Biol Chem 2003; 278: 21831-21836
12. Jiao JG, Li YN, Wang H, Liu Q, Cao JX, Bai RZ, Huang FY. A plasmid DNA vaccine encoding the extracellular domain of porcine endoglin induces anti-tumour immune response against self-endoglin-related angiogenesis in two liver cancer models. Dig Liver Dis 2006; 38: 578-587
13. Hoffmann J, Schirner M, Menrad A, Schneider MR. A highly sensitive model for quantification of in vivo tumor angiogenesis induced by alginate-encapsulated tumor cells. Cancer Res 1997; 57: 3847-3851
14. Folkman J. What is the evidence that tumors are angiogenesis dependent? J Natl Cancer Inst 1990; 82: 4-6
15. Risau W. Mechanisms of angiogenesis. Nature 1997; 386: 671-674
16. Wickham TJ, Haskard D, Segal D, Kovesdi I. Targeting endothelium for gene therapy via receptors up-regulated during angiogenesis and inflammation. Cancer Immunol Immunother 1997; 45: 149-151
17. Gupta MK, Qin RY. Mechanism and its regulation of tumor-induced angiogenesis. World J Gastroenterol 2003; 9: 1144-1155
18. Paleolog EM. Angiogenesis: a critical process in the pathogenesis of RA-a role for VEGF? Br J Rheumatol 1996; 35: 917-919
19. Kerbel RS. Inhibition of tumor angiogenesis as a strategy to circumvent acquired resistance to anti-cancer therapeutic agents. Bioessays 1991; 13: 31-36
20. Boehm T, Folkman J, Browder T, O'Reilly MS. Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance. Nature 1997; 390: 404-407
21. Matsuno F, Haruta Y, Kondo M, Tsai H, Barcos M, Seon BK. Induction of lasting complete regression of preformed distinct solid tumors by targeting the tumor vasculature using two new anti-endoglin monoclonal antibodies. Clin Cancer Res 1999; 5: 371-382
22. Jain RK. Barriers to drug delivery in solid tumors. Sci Am 1994; 271: 58-65
23. Dvorak HF, Nagy JA, Dvorak AM. Structure of solid tumors and their vasculature: implications for therapy with monoclonal antibodies. Cancer Cells 1991; 3: 77-85
24. Denekamp J. Review article: angiogenesis, neovascular proliferation and vascular pathophysiology as targets for cancer therapy. Br J Radiol 1993; 66: 181-196
25. Thorpe PE, Burrows FJ. Antibody-directed targeting of the vasculature of solid tumors. Breast Cancer Res Treat 1995; 36: 237-251
26. Thorpe PE. Vascular targeting agents as cancer therapeutics. Clin Cancer Res 2004; 10: 415-427
27. Folkman J, Shing Y. Angiogenesis. J Biol Chem 1992; 267: 10931-10934
28. Auerbach W, Auerbach R. Angiogenesis inhibition: a review. Pharmacol Ther 1994; 63: 265-311
29. Engerman RL, Pfaffenbach D, Davis MD. Cell turnover of capillaries. Lab Invest 1967; 17: 738-743
30. Risau W. Differentiation of endothelium. FASEB J 1995; 9: 926-933
31. Burrows FJ, Derbyshire EJ, Tazzari PL, Amlot P, Gazdar AF, King SW, Letarte M, Vitetta ES, Thorpe PE. Up-regulation of endoglin on vascular endothelial cells in human solid tumors: implications for diagnosis and therapy. Clin Cancer Res 1995; 1: 1623-1634
32. Seon BK, Matsuno F, Haruta Y, Kondo M, Barcos M. Long-lasting complete inhibition of human solid tumors in SCID mice by targeting endothelial cells of tumor vasculature with antihuman encloglin immunotoxin. Clin Cancer Res 1997; 3: 1031-1044
33. Haruta Y, Seon BK. Distinct human leukemia-associated cell surface glycoprotein GP160 defined by monoclonal antibody SN6. Proc Natl Acad Sci USA 1986; 83: 7898-7902
34. Rokhlin OW, Cohen MB, Kubagawa H, Letarte M, Cooper MD. Differential expression of endoglin on fetal and adult hematopoietic cells in human bone marrow. J Immunol 1995; 154: 4456-4465